Ame Bioscience AS
Score · fiscal year 2023
86of 100
How to read this: the company is ahead of 96 % of companies in the Morning class Micro in the same sector in 2023. What does this mean?
Rank in the Morning class Micro: 438 of 10,548 · What are Morning company classes?
Place in the whole sector: 883 of 21,088 · Handel
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2023, not a verdict on the company. Based on profitability 84 and solidity 87 out of 100 among companies in the Morning class Micro in the same sector in 2023. Methodology
Against the sector
Ame Bioscience AS is 36 points above the median for companies in the Morning class Micro in the same sector in 2023.
Median score 50 among 10,539 companies.
Against companies in the Morning class Micro in the same sector in 2023: operating margin 18.8% (median 2.6%) and equity ratio 76.6% (median 35.5%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 6 MNOK | 4 MNOK |
| Operating margin | 18.8% | 2.6% |
| Profit margin | 18.7% | 2.0% |
| Return on assets | 21.0% | 5.7% |
| Equity ratio | 76.6% | 35.5% |
| Debt-to-equity | 0.31 | 1.26 |
| Current ratio | 4.27 | 1.79 |
| Revenue growth | – | 6.7% |
The median and “ahead of” refer to companies in the Morning class Micro in the same sector in 2023. The bar shows the share of companies the figure is ahead of.
With an index of 86, Ame Bioscience AS does better than 96% of companies in the Morning class Micro in the same sector (10,548 companies) in 2023.
Score 2023–2025
- Ame Bioscience AS
- Median: companies in the Morning class Micro in the same sector
What the numbers say
Ame Bioscience AS had an operating margin of 18.8% and an equity ratio of 76.6% in 2023, and ranks 883 of 21,088 in Handel.
This text is generated automatically from the 2023 accounts.
Three simple methods
The methods give between 4 MNOK and 14 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 8 MNOK |
| EV/EBIT | 8.0 | 14 MNOK |
| P/B | 1.0 | 4 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
- positive
Upper quartile on profitability, solidity and liquidity. What sets this company apart from the rest of the sector?
Based on: Operating margin 18.8% (median 2.6%); Equity ratio 76.6% (median 35.5%); Current ratio 4.27 (median 1.79).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 1.9% of the debt in 2023. The policy rate averaged 3.54 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 84 | weight 30% |
|---|---|---|
| Solidity | 87 | weight 25% |
| Liquidity | 85 | weight 15% |
| Growth | – | no data, left out |
| Consistency | 92 | weight 15% |
Index version 2. Data completeness 85%: the share of the weights that had data.
Questions and answers
How profitable is Ame Bioscience AS?
The operating margin was 18.8% in 2023, against a median of 2.6% among companies in the Morning class Micro in the same sector. Return on assets was 21.0%.
How solid is Ame Bioscience AS?
The equity ratio was 76.6% in 2023 (median 35.5%). Debt-to-equity was 0.31 (median 1.26).
What is the liquidity of Ame Bioscience AS like?
The current ratio was 4.27 in 2023 (median 1.79).
How does Ame Bioscience AS compare in Handel?
Ame Bioscience AS ranks 883 of 21,088 in Handel for 2023. Among companies in the Morning class Micro it is number 438 of 10,548.
From the Central Coordinating Register
- Org. no.
- 988736899
- Legal form
- AS
- Sector
- Handel (46.640)
- Morning company class
- Micro
- Employees
- 0–4 (not registered)
- Founded
- 10 September 2005 21 years in operation
- Share capital
- 0.10 MNOK
- Business address
- Husvikveien 165, 3124 TØNSBERG
- Municipality
- Tønsberg rank 2 of 10 in KOSTRA group 11
- Latest accounts filed
- 2025
- Website
- www.amebioscience.com
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
Loading roles …
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 29 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 86 | 83 | 76 | |
| Rank | 883 | 552 | 1,425 | |
| Operating margin | 18.8% | 20.2% | 20.2% | |
| Return on assets | 21.0% | 38.6% | 29.5% | |
| Equity ratio | 76.6% | 63.5% | 73.9% | |
| Current ratio | 4.27 | 2.74 | 3.84 | |
| Revenue growth | – | 232.2% | −5.2% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 5.8 MNOK | 19.3 MNOK | 18.3 MNOK |
| Operating profit | 1.1 MNOK | 3.9 MNOK | 3.7 MNOK |
| Profit before tax | 1.1 MNOK | 3.9 MNOK | 3.7 MNOK |
| Net profit | 0.8 MNOK | 3.0 MNOK | 2.8 MNOK |
| Financial expenses | 0.0 MNOK | 0.0 MNOK | 0.1 MNOK |
| Total assets | 5.3 MNOK | 10.1 MNOK | 12.6 MNOK |
| Current assets | 5.3 MNOK | 10.1 MNOK | 12.6 MNOK |
| Equity | 4.1 MNOK | 6.4 MNOK | 9.3 MNOK |
| Retained earnings | 3.9 MNOK | 6.3 MNOK | 9.2 MNOK |
| Total liabilities | 1.2 MNOK | 3.7 MNOK | 3.3 MNOK |
| Current liabilities | 1.2 MNOK | 3.7 MNOK | 3.3 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 29 October 2026, accounts id 4789391.
Further
Similar companies
- Steinkjer Gass AS index 86, rank 880 · compare
- MØLLER & Jensen Eiendom AS index 86, rank 882 · compare
- Powertest AS index 86, rank 884 · compare
- International Cooperation AS index 86, rank 885 · compare
- Willy Bye AS index 86, rank 886 · compare